- Home
- ESLT vs LEGN Comparison
ESLT vs LEGN Comparison
Compare ESLT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLT
- LEGN
- Stock Information
- Founded
- ESLT 1966
- LEGN 2014
- Country
- ESLT Israel
- LEGN United States
- Employees
- ESLT N/A
- LEGN N/A
- Industry
- ESLT Military/Government/Technical
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ESLT Industrials
- LEGN Health Care
- Exchange
- ESLT Nasdaq
- LEGN Nasdaq
- Market Cap
- ESLT 8.3B
- LEGN 9.1B
- IPO Year
- ESLT 1996
- LEGN 2020
- Fundamental
- Price
- ESLT $228.70
- LEGN $45.57
- Analyst Decision
- ESLT
- LEGN Strong Buy
- Analyst Count
- ESLT 0
- LEGN 13
- Target Price
- ESLT N/A
- LEGN $81.46
- AVG Volume (30 Days)
- ESLT 23.3K
- LEGN 1.3M
- Earning Date
- ESLT 11-26-2024
- LEGN 11-12-2024
- Dividend Yield
- ESLT 0.88%
- LEGN N/A
- EPS Growth
- ESLT N/A
- LEGN N/A
- EPS
- ESLT 5.44
- LEGN N/A
- Revenue
- ESLT $6,307,469,000.00
- LEGN $455,991,000.00
- Revenue This Year
- ESLT $10.97
- LEGN $108.95
- Revenue Next Year
- ESLT $4.93
- LEGN $81.26
- P/E Ratio
- ESLT $41.76
- LEGN N/A
- Revenue Growth
- ESLT 10.60
- LEGN 176.93
- 52 Week Low
- ESLT $175.30
- LEGN $38.60
- 52 Week High
- ESLT $229.70
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- ESLT 78.03
- LEGN 44.41
- Support Level
- ESLT $207.71
- LEGN $44.56
- Resistance Level
- ESLT $229.70
- LEGN $46.15
- Average True Range (ATR)
- ESLT 2.08
- LEGN 2.05
- MACD
- ESLT 1.71
- LEGN 0.19
- Stochastic Oscillator
- ESLT 96.46
- LEGN 33.83
About ESLT Elbit Systems Ltd.
Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.